Allergan will have four migraine therapies in its portfolio after licensing two oral CGRP antagonists for treatment and prevention of the debilitating headaches from Merck & Co, joining a field crowded with injectable CGRP-targeting biologics.
The companies made sure to note in a 7 July joint announcement that MK-1602 and MK-8031 belong to a different...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
